MDIC Announces Pathology ‘Collaborative Community’ With FDA Involvement
This is MDIC’s third collaborative community, following groups for the US FDA’s Case for Quality and health technology.
You may also be interested in...
The US agency says it has either met or exceeded all its 2018-2020 strategic priorities, including simplifying core processes in its product review pathways.
The US agency is participating in collaborative communities centered around eye health and the development of real-world evidence, representing the first two of what the agency hopes will be at least 10 communities by the end of 2020.
The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.